Abstract: Deregulation of intracellular calcium homeostasis is a common hallmark of degenerating neurons, at some point of the cell death cascade. It is also a feature of many neurological disorders, including stroke, epilepsy, trauma and several neurodegenerative diseases, commonly associated with the phenomenon of excitotoxicity. Nitric oxide (NO) is a signaling gaseous molecule formed in the brain as a part of the normal intracellular calcium signalling, playing highly diversified parts in cellular physiology. For the past 20 years, numerous studies have demonstrated that NO acts as a neurotoxin in several disorders of the nervous system. More recent evidence shows that NO can also act as a neuroprotective agent. Calcium-dependent proteases, like calpains, were also shown to be activated in several conditions of the nervous system that involve excitotoxic neurodegeneration, and have been receiving increasing attention as therapeutical targets in the recent years. In this commentary, we bring together the recent literature concerning the involvement of NO and calpains in neuronal death and survival. NO pathways and calpains are good candidates in what concerns therapeutic intervention, but new drugs are needed.
INTRODUCTION
composition), or through voltage-sensitive Ca 2+ channels (VSCC) following neuronal depolarization, reversal of the NCX and release from intracellular stores ( Fig. 1 ) [2] . Overactivation of glutamate receptors is toxic to neuronal cells in a Ca 2+ -dependent manner [3] [4] [5] [6] , and the phenomenon of cellular toxicity by which glutamate leads to neuronal death is known as excitotoxicity, first described by Olney in 1969 [7] . Ca 2+ acts as a death trigger in neurons due to an intracellular overload, and is also a key second messenger that leads to activation of Ca 2+ -dependent enzymes.
In this commentary we discuss recent findings highlighting the physiological and pathophysiological role of nitric oxide (NO) and calpain activation. Both the production of NO by nitric oxide synthase and the activation of calpains are regulated by Ca 2+ . Thus, after a brief overview of the regulation of [Ca 2+ ] i in the neuronal cell, we bring together the recent literature concerning the involvement of NO and calpains in neuronal death and survival.
Excitotoxicity and supraphysiological activation of glutamate receptors have been implicated and thoroughly discussed in the pathological mechanisms of several neurological conditions that comprehend neurodegeneration, such as cerebral ischemia [8] , traumatic brain injury [9] , epilepsy [3] , amyotrophic lateral sclerosis [10] , Alzheimer's disease [11] , Parkinson's disease [12] , and Huntington's disease [13] , among others. Nevertheless, some of the mechanisms by which increased Ca 2+ causes excitotoxic cell death are still unclear and need to be further explored.
The delicate balance of neuronal physiology can be easily perturbed by changes in the intracellular calcium concentration ( [Ca 2+ ] i ) as a consequence of normal excitatory neurotransmission. In basal conditions, [Ca 2+ ] i is about 100 nM, and synaptic stimulation raises [Ca 2+ ] i in cell bodies up to the micromolar range. In physiological conditions, several cellular entities carry out the task of bringing calcium levels back to basal values, such as the Na + /Ca 2+ exchanger (NCX), the plasma-membrane Ca 2+ -ATPase (PCMA), the endoplasmic reticulum (ER), and also mitochondria (Fig. 1) . In pathophysiological conditions, impairment of these mechanisms of Ca 2+ extrusion, buffering, binding and sequestration may cause a deregulated increase in [Ca 2+ ] i , which then acts as a trigger for neuronal death and degeneration (last reviewed by Orrenius et al. in [1] ).
I. NITRIC OXIDE IN THE BRAIN: PHYSIOLOGY AND PATHOPHYSIOLOGY
Garthwaite et al. [21] were among the first to describe a link between glutamate and NO, a free radical molecule with sui generis abilities as a messenger. The factor shown to mediate the increase in cyclic GMP (cGMP) levels, following activation of NMDA receptors, was first known as endothelial derived relaxing factor [22] , due to its involvement in blood vessel reactivity and smooth muscle relaxation. Later recognized as the gaseous molecule NO [23] , this free radical has so far been reported to be involved in physiologic mechanisms that range from the vascular system, penile erection, inflammatory responses, to the broad functions it plays in the nervous system. Widely accepted as an endogenous messenger, signal mediator, and non-classical neurotransmitter, NO is one of the most plastic signaling molecules so far described in biological systems.
In the mammalian central nervous system (CNS), glutamate is the main excitatory neurotransmitter. Glutamate acts on metabotropic and ionotropic glutamate receptors, of which the latter are known to increase [Ca 2+ ] i , which can enter the cell either directly through the Ca 2+ -permeable ionotropic glutamate receptors (mainly NMDA or through some AMPA receptors, depending on the subunit Fig. (1) . Overactivation of ionotropic glutamate receptors causes Ca 2+ influx through the NMDA receptor and through some Ca 2+ -permeable AMPA receptors and increases the [Ca 2+ ] i (eg. [14] ). Following neuronal depolarization, Ca 2+ can also enter the cell through voltage-sensitive calcium channels (VSCC) or through the Na + / Ca 2+ exchanger (NCX) operating in the reverse mode. In physiological conditions, the NCX, the plasma membrane Ca 2+ -ATPase (PMCA), the endoplasmic reticulum (ER) and mitochondria are responsible for bringing the [Ca 2+ ] i back to basal values; when this mechanisms are impaired, Ca 2+ can return to the cytoplasm by release from the ER and the mitochondria, as well as reversal of the NCX. An increase in [Ca 2+ ] i can trigger the activation of nitric oxide synthase (NOS) and production of nitric oxide (NO), following activation of NMDA (eg. [15] ) or AMPA receptors (eg. [16] ), which can react with superoxide anion (O 2-) formed in the mitochondria (eg. [17] ) to form the more toxic form, peroxynitrite (ONOO -)(eg. [18] ). Both NO and ONOO -are neurotoxic and cause neuronal death. Calpains can also be activated by an increase in [Ca 2+ ] i , cause by activation of NMDA or AMPA receptors ( [19, 20] , participating in the proteolysis of many intracellular proteins and leading to neuronal demise.
NO is produced in biological systems by nitric oxide synthase (NO), which catalyses NO formation from the oxidation of L-arginine to L-citrulline. Three different isoforms were so far described, based on their biochemical, pharmacological and regulatory properties, as well as distinct tissue localization: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Both nNOS and eNOS are dependent on Ca 2+ for activation, while iNOS activity is independent of the Ca 2+ concentration and regulated at the transcriptional level (reviewed in [24] ). Most of the biological effects of NO are mediated by cyclic GMP (cGMP) [25] . Guanylyl cyclase is the primary target for NO in the brain, which binds to the heme group of guanylyl cyclase and stimulates the enzyme to convert GTP to cGMP [26] . cGMP has the ability to act upon cGMP-dependent ion channels and activates protein kinase G (PKG), which then modulates the activity of a variety of different cellular substrates. their activity changed by this mechanism, such as p21ras [28] , glyceraldehyde-3-phosphate dehydrogenase [29] , caspase-3 [30] , and the NMDA receptor [31] . For instance, S-nitrosylation of caspase-3 [30] , as well as of other caspases [32] , has an anti-apoptotic effect, thus acting as a protective mechanism against apoptosis [33] . The discovery of which of these targets are indeed modulated by endogenous NO in vivo has shed new light upon the physiological roles of NO, highlighting S-nitrosylation as a physiological signaling mechanism for NO, with a new perspective of Snitrosylation as a regulatory process and post-translational modification for proteins [34] .
One of the most interesting aspects of NO in the brain is the regulation of the release of neurotransmitters. NO produced in the presynaptic terminal or at postsynaptic sites, and acting as a retrograde messenger, was shown to stimulate the release of glutamate, either by Ca 2+ -dependent mechanisms and direct stimulation of exocytosis from synaptic vesicles by S-nitrosylation of proteins involved in exocytosis [35] . In fact, a recent report has shown that NO can regulate exocytosis by S-nitrosylation of Nethylmaleimide-sensitive factor [36] . Another possibility is NO can also have modulatory effects on several proteins due to a direct interaction with cysteine residues in proteins, forming nitrosothiol adducts, by a reversible and regulatory process known as S-nitrosylation [27]. Several proteins see by Ca 2+ -independent processes, which likely involve reversal of the glutamate carrier [37] . Besides glutamate, NO is also involved in the regulation of the release of monoamines [38] , taurine [39] , and adenosine [40] . Since NO is so involved in the enhancement of neurotransmitter release, this could possibly be one of the mechanisms by which it is also involved in synaptic plasticity, next described.
polymerase (PARP) and subsequent depletion of cellular ATP and NADPH levels [60] , as well as inhibition of mitochondrial activity and ATP production [61] [62] [63] . Furthermore, it is widely accepted now that many of the deleterious effects of NO are likely mediated by the more toxic form, peroxynitrite, which results from the reaction of NO with the superoxide anion ( Fig. 1) [64, 65] . Concerning the effects of NO on the neurotoxicity mediated by non-NMDA receptors, previous reports have shown that NO is somehow involved in the neurotoxic effect of kainate (KA) to cultured neurons [66, 67] . Recently, our group reported that inhibition of NO synthase is neuroprotective against the neurotoxicity mediated by activation of AMPA receptors [16] . Besides NO, also peroxynitrite is produced following activation of AMPA receptors in hippocampal neurons, which is reflected at the mitochondrial level [18] .
NO is known to be involved in the modulation of synaptic plasticity, with implications for memory and learning phenomena. Particularly, in hippocampal circuitries, NO was shown to be involved in long-term potentiation (LTP) [41, 42] , a form of synaptic plasticity that strengthens synaptic transmission and which is thought to underlie the basic mechanisms of memory in the hippocampus [43] . In the particular case of LTP, it is known that NOS-deficient mice have impairments in the development of LTP [44] and pharmacological inhibition of NOS blocks LTP [45] . It is accepted that NO affects the LTP phenomenon through a cGMP-dependent mechanism [46, 47] . NO is also involved in long-term depression, another form of synaptic plasticity [48] . Indeed, a large body of evidence suggests that NO is involved in memory formation and storage [49] .
As a free radical, NO was shown to be involved in several conditions that involve oxidative stress (an increased production of reactive oxygen or nitrogen species together with an impairment of the cellular antioxidant defenses, resulting in an imbalance of oxidative reactions). Particularly, in brain ischemia, NO was shown to be detrimental to neuronal survival, but evidence also points out the fact that NO can help the recovery of the ischemic brain through stimulation of angioenesis and neurogenesis (thoroughly reviewed by Keynes and Garthwaite in [68] ). The involvement of NO in several neurodegenerative disorders was recently discussed previously by others, as is the case for its role in the pathogenesis of Parkinson's disease [69] , Huntington's disease [70] , Alzheimer's disease [71] , amyotrophic lateral sclerosis [72] , as well as in brain aging [73] , and will not be further discussed here. Overall, NO appears to be detrimental as a neurotoxin in neurodegenerative conditions, although it may produce some beneficial effects through regulation of neurogenesis and repair.
NO also has the interesting ability to compete with oxygen for the binding site at mitochondrial complex IV (cytochrome oxidase), inhibiting the enzyme in a reversible manner [50, 51] . A growing body of evidence suggests that endogenous NO can act as a physiological modulator of mitochondrial respiration, thus controlling the rate of ATP synthesis and cellular bioenergetics [52] , and for the brain, which depends mostly on oxidative phosphorylation for obtention of energy, this fact may be of particular relevance. A prolonged increase in NO may cause depletion of the cellular ATP levels and thus lead to neuronal demise [53] .
Recently, NO was described as a modulator of neurogenesis in the CNS, a process that occurs in the adult brain in two limited areas, the subventricular zone and the dentate gyrus in the hippocampus. Endogenous NO appears to be inhibiting neurogenesis in these two neurogenic areas, as demonstrated by the treatment with inhibitors of NOS or in nNOS knockout mice [54, 55] . One of the possible mechanisms for this negative regulatory effect of NO on neurogenesis could be mediated by a decreased expression of the oncogene N-Myc [56] . On the other hand, NO of inflammatory origin, which is produced in high amounts, appears to be promoting neurogenesis in the damaged ischemic brain [57] . In fact, NO-releasing drugs enhance neurogenesis and promote functional recovery of animal models of ischemic stroke [58] and traumatic brain injury [59] . Apparently, depending on the pathophysiological state of the tissue and on the source, NO appears to have a dual effect on the regulation of adult neurogenesis. The actual knowledge on the role of NO as a modulator of cell proliferation, neuronal differentiation and survival of newly born neurons is still being gathered, and new findings will no doubt emerge in the coming years.
Within this scenario, the Janus face of NO is reflected in its neurotoxic/neuroprotective profile in the CNS, where its actions can be highly diversified, according to the site of production, its source and the overall condition of the neuronal cells. Due to its effects on neurotransmitter release, neuronal bioenergetics, regulation of neuronal proliferation and differentiation and neurotoxic/neuroprotective profile, NO is a likely candidate for therapeutic intervention in disorders comprehending neuronal damage and excitotoxicity. In fact, several drugs are being evaluated as potential NO-based therapies for neuroprotective approaches to pathologies in which NO is known to be involved [74] .
II. CALPAINS AND PROTEOLYTIC MECHANISMS IN NEURONAL DEGENERATION AND SURVIVAL
Proteases are under a tight regulatory control, which is disrupted by sustained increases in intracellular calcium concentration. Calpains, or calcium-activated neutral proteases, are directly activated by binding of Ca 2+ upon an increase in [Ca 2+ ] i . The involvement of calpains in neuronal pathophysiology is discussed below, as well as their crosstalk with the caspase family during excitotoxic neurodegeneration in pathophysiological states and its relevance to some neurodegenerative disorders.
For the past 15 years, NO has also been implicated as a mediator of glutamate induced-neuronal damage via NMDA receptors [15] . Several mechanisms have been suggested for the action of NO as a neurotoxin in glutamate-induced neurotoxicity, namely through activation of poly-ADPribose Calpains were first involved in excitotoxic neuronal death as effectors of calcium induced-injury by Siman and Noszek (1988) . µ-Calpain and m-calpain are ubiquitous in mammalian cells, and several tissue-specific calpains have been described [75, 76] . The designations µ-calpain (or calpain I) and m-calpain (or calpain II) refer to the calcium requirements for enzyme activity, micromolar or millimolar concentrations of calcium are required for activation of each isoform, respectively. Both enzymes are heterodimers composed by a large catalytic subunit of approximately 80 kD, with a cysteine protease domain and a calcium-binding domain with four helix-loop-helix (EF-hand) structures, and by a small regulatory subunit of 28 kD with another 4 EFhand structures (for review, see [76] ). Upon binding of calcium following an increase in intracellular concentration, calpains suffer a conformational change and undergo autolysis or autoproteolysis. The large 80 kD subunit is processed to a 76 kD form, and the small 28 kD subunit is converted to a 18 kD form. After autolysis, activated calpains require smaller increases in intracellular calcium concentration for activation. neurodegeneration in several disorders [91, 92] . Calpains may also regulate gene expression at the activational level, since they can regulate the translocation of transcription factors like NFkappaB from the cytoplasm to the nucleus, through proteolytic cleavage of the IkappaBalpha inhibitor in neuronal cells exposed to glutamate [93] .
Furthermore, like caspases, calpains are also implicated in excitotoxic neurodegeneration elicited by glutamate via NMDA receptors [19, 90, 94] . Concerning the neurotoxicity mediated by AMPA receptors, little is know about which proteases are involved in cell death. There is some evidence that caspase-3 is activated following exposure to AMPA in cultured hippocampal neurons [17] , but it is not known if it is contributing as an effector of cell death. In fact, we recently described an early activation of calpains following activation of AMPA receptors, and the blockade by calpain inhibitors affords neuroprotection to hippocampal neurons [20] . Interestingly, calpains are also linked to the NO pathway. We recently demonstrated that cleavage of nNOS by calpains limits the involvement of NO in the neurotoxicity mediated by activation of AMPA receptors [16] . To date, only one endogenous inhibitor for calpains is known, calpastatin. This protein selectively inhibits both µ-calpain and m-calpain, and is composed of four repeats of calpain inhibitory domains (CID). Calpastatin plays a pivotal role in the cell death pathways in several models, since it is responsible for a functional interplay between calpains and caspases. The caspases are a large family of proteases largely associated with apoptotic cell death, which can be activated by proteolytic processing following mitochondrial dysfunction due to calcium overload or by membranar events associated with binding of death-signaling ligands. Calpastatin is a substrate for caspase-3, and caspase-3 activation can facilitate calpain activation due to removal of the calpastatin blockade through its proteolysis by caspase-3 [77, 78] , and this crosstalk phenomenon was shown to occur during neuronal apoptosis [79] . On the other hand, m-calpain is also able to cleave caspase-3 and further facilitates caspase activation and apoptotic progression, both in vitro as well as in an in vivo model of perinatal ischemia [80] , in a calpastatin-sensitive manner. Thus, calpastatin appears to play a pivotal role in the crosstalk at the activational level that occurs between caspases and calpains during cell death. Complex interactions are observed between calpains and caspases during pathological conditions at substrate cleavage, proteolytic activation and modulation of endogenous inhibitors levels, suggesting that the crosstalk between the two families of proteases may influence the outcome for neuronal viability following a given insult.
In many diseases comprising excitotoxicity, calpains were implicated as part of the neurodegenerative mechanisms. Both in slow neurodegenerative disorders, as in acute conditions such as stroke, epilepsy or traumatic brain damage, many data have been gathered and compiled concerning the involvement of calpains, either in the initial stages of disease development or as killer agents that participate in neuronal cell death [92, [95] [96] [97] [98] . Several studies have been conducted evaluating the neuroprotective and functional recovery potential of short-lived calpain inhibitors in a variety of disease models for ischemic stroke and brain trauma [99] [100] [101] [102] [103] [104] , with promising results in what concerns smaller infarction volumes and behavioral recovery. In animal models of temporal lobe epilepsy, namely in the kainic acid rat model, evidence for a strong calpain activation was also found in the hippocampus and other brain regions following status epilepticus [105] [106] [107] [108] , suggesting that calpains may be involved in excitotoxic neurodegeneration in the brain of epileptic rats, namely through proteolysis of subunits of the ionotropic glutamate receptors GluR1 [85, 109] and NR2B [108] .
Abnormal cleavage of proteins by proteases is a common motif in neurodegenerative disorders. This is the case of huntingtin, a large cytoplasmic protein of yet unknown function and that occurs mutated in Huntington's disease. This protein was recently described to have cleavage recognition sites for calpains [110] , as well as for caspases [111] . Cleavage of huntingtin occurs in HD patients, precedes neurodegeneration and may be responsible for the formation of aggregates [112] , and thus the identification of the role of calpains in the proteolytic cleavage of mutant huntingtin is certainly of relevance for the further understanding of the pathogenesis of this neurodegenerative condition. In the MPTP mouse model of Parkinson's disease, calpains are involved in neuronal damage and inhibition of calpains is neuroprotective [113] . Interestingly, cleavage of mutated alpha-synuclein (present in some forms of familial Parkinson's disease) by calpains was shown to be neuroprotective in an immortalized hippocampal cell line Several proteins are calpain substrates, and some are also substrates for effector caspases (for review see [81] ). Among many of the substrates are membranar receptors like the epidermal growth factor receptor [82] and subunits of NMDA [83, 84] and AMPA receptors [85] , cytoskeletal proteins (like spectrin, actin, MAP-2, for instance), protein kinases like calcium-calmodulin protein kinase [86] , protein kinase A [87] and protein kinase C [88] , and phosphatases like calcineurin [89] . More recently, the activation of calpain was shown to promote a shift from apoptotic cell death to necrosis [90] , and the cleavage of such protein substrates has been implicated in the pathological mechanisms of that overexpress parkin [114] , thus providing new insight into the possible role of calpains as neuroprotective agents. However, the precise involvement of calpains at the several stages of disease progression in Parkinson's disease patients is unknown and yet to be determined. In Alzheimer's disease, calpains were shown to be involved in several steps of the formation of amyloid plaques formation and neurodegeneration process. The participation of calpains in the several stages of Alzheimer's disease prior to marked cell death: calpains modulate the phosphorylation and proteolysis of the microtubule-associated protein tau, through regulation of the activities of protein kinase C and cdk-5, ultimately leading to tau hyperphosphorylation [92, 115] . Several calpain inhibitors have proved to be neuroprotective in animal models of neurodegeneration and were recently reviewed [97] . The identification of the intracellular targets for calcium in neurological disorders is of ultimate importance for designing therapeutical approaches. The NO pathway and calpains are good candidates in what concerns therapeutic intervention, but new drugs need to be developed in what concerns selectivity, solubility, permeability to the bloodbrain barrier, and therapeutic windows. The modest success so far accomplished needs further improvement concerning better recovery after insult and applicability to human patients. Nevertheless, it should be stated that interfering with the pathways of cell death is a double-edged sword: even if prevention of neuronal damage and enhancement of neuronal repair are ideally accomplished, on the long run, extreme care should be taken in what concerns anti-cell death drugs, due to risk of deregulated cell proliferation and tumor incidence. Thus, along with a stronger investment on drug discovery, more mechanistic insight is needed on the neurodegenerative processes triggered by deregulation of intracellular calcium homeostasis, to proceed with the precise identification of therapeutic targets.
